Literature DB >> 16142730

Localized scleroderma in childhood is not just a skin disease.

Francesco Zulian1, Cristina Vallongo, Patricia Woo, Ricardo Russo, Nicolino Ruperto, John Harper, Graciela Espada, Fabrizia Corona, Masha Mukamel, Richard Vesely, Elzbieta Musiej-Nowakowska, Jeff Chaitow, Joan Ros, Maria T Apaz, Valeria Gerloni, Henryka Mazur-Zielinska, Susan Nielsen, Susanne Ullman, Gerd Horneff, Carine Wouters, Giorgia Martini, Rolando Cimaz, Ronald Laxer, Balu H Athreya.   

Abstract

OBJECTIVE: Juvenile localized scleroderma is usually considered a disease that is confined to the skin and subcutaneous tissue. We studied the prevalence and clinical features of extracutaneous manifestations in a large cohort of children with juvenile localized scleroderma.
METHODS: Data from a multinational study on juvenile scleroderma was used for this in-depth study. Clinical features of patients with extracutaneous manifestations were compared with those of patients who had exclusively skin involvement.
RESULTS: Seven hundred fifty patients entered the study. One hundred sixty-eight patients (22.4%) presented with a total of 193 extracutaneous manifestations, as follows: articular (47.2%), neurologic (17.1%), vascular (9.3%), ocular (8.3%), gastrointestinal (6.2%), respiratory (2.6%), cardiac (1%), and renal (1%). Other autoimmune conditions were present in 7.3% of patients. Neurologic involvement consisted of epilepsy, central nervous system vasculitis, peripheral neuropathy, vascular malformations, headache, and neuroimaging abnormalities. Ocular manifestations were episcleritis, uveitis, xerophthalmia, glaucoma, and papilledema. In more than one-fourth of these children, articular, neurologic, and ocular involvements were unrelated to the site of skin lesions. Raynaud's phenomenon was reported in 16 patients. Respiratory involvement consisted essentially of restrictive lung disease. Gastrointestinal involvement was reported in 12 patients and consisted exclusively of gastroesophageal reflux. Thirty patients (4%) had multiple extracutaneous features, but systemic sclerosis (SSc) developed in only 1 patient. In patients with extracutaneous involvement, the prevalence of antinuclear antibodies and rheumatoid factor was significantly higher than that among patients with only skin involvement. However, Scl-70 and anticentromere, markers of SSc, were not significantly increased.
CONCLUSION: Extracutaneous manifestations of juvenile localized scleroderma developed in almost one-fourth of the children in this study. These extracutaneous manifestations often were unrelated to the site of the skin lesions and sometimes were associated with multiple organ involvement. The risk of developing SSc was very low. This subgroup of patients with juvenile localized scleroderma should be evaluated extensively, treated more aggressively, and monitored carefully.

Entities:  

Mesh:

Year:  2005        PMID: 16142730     DOI: 10.1002/art.21264

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  74 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  Parry-Romberg syndrome.

Authors:  Elizabeth Lazaridou; Christina Giannopoulou; Zoi Apalla; Christina Fotiadou; Anastasia Trigoni; Demetris Ioannides
Journal:  J Dermatol Case Rep       Date:  2010-11-19

Review 3.  A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.

Authors:  Liza J McCann; Clare E Pain
Journal:  Indian J Pediatr       Date:  2016-02       Impact factor: 1.967

Review 4.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

5.  Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma.

Authors:  Kaveh Ardalan; Christina K Zigler; Kathryn S Torok
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-07       Impact factor: 4.794

6.  Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Kathryn S Torok; Thomas A Medsger
Journal:  Rheumatology (Oxford)       Date:  2009-12-14       Impact factor: 7.580

7.  Ocular involvement in children with localised scleroderma: a multi-centre study.

Authors:  Maria Elisabetta Zannin; Giorgia Martini; Balu H Athreya; Ricardo Russo; Gloria Higgins; Fabio Vittadello; Maria Giannina Alpigiani; Mariolina Alessio; Mauro Paradisi; Patricia Woo; Francesco Zulian
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

8.  Sonographic evaluation of pediatric localized scleroderma: preliminary disease assessment measures.

Authors:  Suzanne C Li; Melissa S Liebling; Faridali G Ramji; Sven Opitz; Arun Mohanta; Tatiana Kornyat; Shuzhen Zhang; Molly Dempsey-Robertson; Carsten Hamer; Stephanie Edgerton; Jose Jarrin; Mike Malone; Andrea S Doria
Journal:  Pediatr Rheumatol Online J       Date:  2010-04-27       Impact factor: 3.054

Review 9.  [Scleroderma in childhood and adolescence. New aspects on classification, etiology and therapy].

Authors:  H J Girschick
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

10.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.